Are short telomeres predictive of advanced cancer?

Cancer Discovery

Volumn 3, Issue 10, 2013, Pages 1096-1098

  Shay, Jerry W ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; IMETELSTAT; TELOMERASE; TELOMERASE INHIBITOR; TELOMERASE REVERSE TRANSCRIPTASE;

ADVANCED CANCER; ALTERNATIVE RNA SPLICING; ARTICLE; CANCER MORTALITY; DNA DAMAGE CHECKPOINT; DRUG TARGETING; HUMAN; INFLAMMATION; INFLAMMATORY INFILTRATE; LUNG NON SMALL CELL CANCER; METASTASIS; OXIDATIVE STRESS; PHASE 2 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATECTOMY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; STROMA CELL; TELOMERASE REVERSE TRANSCRIPTASE GENE; TELOMERE HOMEOSTASIS;

ANIMALS; DISEASE PROGRESSION; HUMANS; INDIVIDUALIZED MEDICINE; MALE; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS; RATS; TELOMERE; TUMOR MARKERS, BIOLOGICAL;

EID: 84885601539     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-13-0506     Document Type: Article

References (12)

1. Gomes NMV, Ryder OA, Houck ML, Charter SJ, Walker W, Forsyth NR, et al. The comparative biology of mammalian telomeres: ancestral states and functional transitions. Aging Cell 2011; 10: 761-8.
2. Kim N-W, Harley CB, Prowse KR, Weinrich SL, Piatyszek MA, Wright WE, et al. Telomeres, telomerase and cancer. Science 1995; 268: 1115-7.
3. Shay JW, Wright WE. Implications of mapping the human telomerase genes (hTERT) as the most distal gene on chromosome 5p. Neoplasia 2000; 2: 195-6.
4. Willeit P, Willeit J, Mayr A, Weger S, Oberhollenzer F, Brandstätter A, et al. Telomere length and risk of incident cancer and cancer mortality. JAMA 2010; 304: 69-75.
5. Tchkonia T, Zhu Y, van Deursen J, Campisi J, Kirkland JL. Cellular senescence and the senescent secretory phenotype: therapeutic opportunities. J Clin Invest 2013; 123: 966-72.
6. Heaphy CM, Yoon GS, Peskoe SB, Joshu CE, Lee TK, Giovannucci E, et al. Prostate cancer cell telomere length variability and stromal cell telomere length as prognostic markers for metastasis and death. Cancer Discov 2013;3:1130-41.
7. Meeker AK, Hicks JL, Platz EA, March GE, Bennett CJ, Delannoy MJ, et al. Telomere shortening is an early somatic DNA alteration in human prostate tumorigenesis. Cancer Res 2002; 62: 6405-9.
8. Sommerfeld H, Meeker AK, Piatyszek MA, Bova GS, Shay JW, Coffey DS. Telomerase activity: a prevalent marker of malignant human prostate tissue. Cancer Res 1996; 56: 218-22.
9. Marian CO, Shay JW. Telomerase inhibition therapy to target prostate tumor-initiating cells. Biochim Biophys Acta 2009; 1792: 289-96.
10. Marian CO, Wright WE, Shay JW. The effect of telomerase inhibition on prostate tumor-initiating cells. Int J Cancer 2010; 127: 321-31.
11. De Marzo AM, Marchi VL, Epstein JI, Nelson WG. Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am J Pathol 1999; 155: 1985-92.
12. Canales BK, Li Y, Thompson MG, Gleason JM, Chen Z, Malaeb B, et al. Small molecule, oligonucleotide-based telomerase template inhibition in combination with cytolytic therapy in an in-vitro androgenindependent prostate cancer model. Urol Oncol 2006; 24: 141-51.